2022
DOI: 10.1007/s40122-022-00417-6
|View full text |Cite
|
Sign up to set email alerts
|

First Report of Symmetrical Drug-related Intertriginous and Flexural Exanthema (SDRIFE or Baboon Syndrome) After Erenumab Application for Migraine Prevention

Abstract: Introduction: Symmetrical drug-related intertriginous and flexural exanthema (SDRIFE), formerly also called baboon syndrome, is characterized by symmetrical erythematous rash with typical localization in the gluteal and intertriginous areas. A type IV delayed hypersensitivity immune response is thought to be responsible for its development. CGRP monoclonal antibodies (CGRP mAbs) are a new class of drugs for the prevention of migraine. We present the first case of SDRIFE occurring in temporal relation to the us… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

0
4
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
5
1

Relationship

0
6

Authors

Journals

citations
Cited by 7 publications
(4 citation statements)
references
References 49 publications
0
4
0
Order By: Relevance
“…Adverse reactions associated with these medications are generally mild to moderate, primarily including asthenia, drowsiness, nausea, dizziness, paresthesias, fatigue, vertigo, weight loss, altered taste, and anorexia. Moreover, researchers in clinical trials have focused on severe adverse drug reactions ( 60 , 61 ), drug discontinuation events ( 62 ), the safety of combination therapies ( 63 ), the safety of medication for patients with underlying conditions ( 64 ), the safety of medication during specific physiological periods ( 65 ), migraine types associated with specific symptoms ( 66 ), various methods of administration ( 67–69 ), and the reporting of rare drug-related cases ( 70 ).…”
Section: Discussionmentioning
confidence: 99%
“…Adverse reactions associated with these medications are generally mild to moderate, primarily including asthenia, drowsiness, nausea, dizziness, paresthesias, fatigue, vertigo, weight loss, altered taste, and anorexia. Moreover, researchers in clinical trials have focused on severe adverse drug reactions ( 60 , 61 ), drug discontinuation events ( 62 ), the safety of combination therapies ( 63 ), the safety of medication for patients with underlying conditions ( 64 ), the safety of medication during specific physiological periods ( 65 ), migraine types associated with specific symptoms ( 66 ), various methods of administration ( 67–69 ), and the reporting of rare drug-related cases ( 70 ).…”
Section: Discussionmentioning
confidence: 99%
“… 5 Apart from injection site reactions, the only cutaneous adverse effects reported due to erenumab are a case of symmetrical drug-related intertriginous and flexural exanthema and impaired wound healing. 5 , 6 , 7 …”
Section: Discussionmentioning
confidence: 99%
“…The roles for CLR function in other than skin tissues, and its implication in diseases and disorders such as clear cell renal cell carcinoma (CCRCC), acute myeloid leukaemia (AML), stroke and migraine have been reported (Angenendt et al, 2019;Edvinsson et al, 2018;Gluexam et al, 2019;Herlambang et al, 2021;Koyama et al, 2017;Larrue et al, 2021;Nikitenko, Leek, et al, 2013). The use of monoclonal antibody-based drugs targeting CLR-mediated function for migraine prophylaxis, such as erenumab and galcanezumab, has been associated with impaired wound healing in skin, along with development of skin reactions and side effects such as swelling, rashes or pruritus (Bangs et al, 2020;Wurthmann et al, 2020;Göbel et al, 2022;Schenk et al, 2022).…”
Section: Introductionmentioning
confidence: 99%